Bauerschmitz, Gerd Johannes

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Hellinger, Johanna W."],["dc.contributor.author","Schömel, Franziska"],["dc.contributor.author","Buse, Judith V."],["dc.contributor.author","Lenz, Christof"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.author","Emons, Günter"],["dc.contributor.author","Gründker, Carsten"],["dc.date.accessioned","2021-04-14T08:31:47Z"],["dc.date.available","2021-04-14T08:31:47Z"],["dc.date.issued","2020"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1038/s41598-020-74838-8"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17824"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83712"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2045-2322"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","906"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Der Gynäkologe"],["dc.bibliographiccitation.lastpage","913"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Hellriegel, M."],["dc.contributor.author","Bauerschmitz, G."],["dc.contributor.author","Emons, G."],["dc.date.accessioned","2020-12-10T14:08:44Z"],["dc.date.available","2020-12-10T14:08:44Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00129-017-4162-8"],["dc.identifier.eissn","1433-0393"],["dc.identifier.issn","0017-5994"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70535"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Palliativmedizinische Konzepte beim Mammakarzinom"],["dc.title.alternative","Palliative medical concepts in breast cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1089"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Geburtshilfe und Frauenheilkunde"],["dc.bibliographiccitation.lastpage","1109"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Emons, Günter"],["dc.contributor.author","Steiner, Eric"],["dc.contributor.author","Vordermark, Dirk"],["dc.contributor.author","Uleer, Christoph"],["dc.contributor.author","Bock, Nina"],["dc.contributor.author","Paradies, Kerstin"],["dc.contributor.author","Ortmann, Olaf"],["dc.contributor.author","Aretz, Stefan"],["dc.contributor.author","Mallmann, Peter"],["dc.contributor.author","Kurzeder, Christian"],["dc.contributor.author","Hagen, Volker"],["dc.contributor.author","van Oorschot, Birgitt"],["dc.contributor.author","Höcht, Stefan"],["dc.contributor.author","Feyer, Petra"],["dc.contributor.author","Egerer, Gerlinde"],["dc.contributor.author","Friedrich, Michael"],["dc.contributor.author","Cremer, Wolfgang"],["dc.contributor.author","Prott, Franz-Josef"],["dc.contributor.author","Horn, Lars-Christian"],["dc.contributor.author","Prömpeler, Heinrich"],["dc.contributor.author","Langrehr, Jan"],["dc.contributor.author","Leinung, Steffen"],["dc.contributor.author","Beckmann, Matthias"],["dc.contributor.author","Kimmig, Rainer"],["dc.contributor.author","Letsch, Anne"],["dc.contributor.author","Reinhardt, Michael"],["dc.contributor.author","Alt-Epping, Bernd"],["dc.contributor.author","Kiesel, Ludwig"],["dc.contributor.author","Menke, Jan"],["dc.contributor.author","Gebhardt, Marion"],["dc.contributor.author","Steinke-Lange, Verena"],["dc.contributor.author","Rahner, Nils"],["dc.contributor.author","Lichtenegger, Werner"],["dc.contributor.author","Zeimet, Alain"],["dc.contributor.author","Hanf, Volker"],["dc.contributor.author","Weis, Joachim"],["dc.contributor.author","Mueller, Michael"],["dc.contributor.author","Henscher, Ulla"],["dc.contributor.author","Schmutzler, Rita"],["dc.contributor.author","Meindl, Alfons"],["dc.contributor.author","Hilpert, Felix"],["dc.contributor.author","Panke, Joan"],["dc.contributor.author","Strnad, Vratislav"],["dc.contributor.author","Niehues, Christiane"],["dc.contributor.author","Dauelsberg, Timm"],["dc.contributor.author","Niehoff, Peter"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Grab, Dieter"],["dc.contributor.author","Kreißl, Michael"],["dc.contributor.author","Witteler, Ralf"],["dc.contributor.author","Schorsch, Annemarie"],["dc.contributor.author","Mustea, Alexander"],["dc.contributor.author","Petru, Edgar"],["dc.contributor.author","Hübner, Jutta"],["dc.contributor.author","Rose, Anne"],["dc.contributor.author","Wight, Edward"],["dc.contributor.author","Tholen, Reina"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.author","Fleisch, Markus"],["dc.contributor.author","Juhasz-Boess, Ingolf"],["dc.contributor.author","Lax, Sigurd"],["dc.contributor.author","Runnebaum, Ingo"],["dc.contributor.author","Tempfer, Clemens"],["dc.contributor.author","Nothacker, Monika"],["dc.contributor.author","Blödt, Susanne"],["dc.contributor.author","Follmann, Markus"],["dc.contributor.author","Langer, Thomas"],["dc.contributor.author","Raatz, Heike"],["dc.contributor.author","Wesselmann, Simone"],["dc.contributor.author","Erdogan, Saskia"],["dc.date.accessioned","2020-12-10T18:12:05Z"],["dc.date.available","2020-12-10T18:12:05Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1055/a-0715-2964"],["dc.identifier.eissn","1438-8804"],["dc.identifier.issn","0016-5751"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74238"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","418"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Woelber, Linn; 1Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg—Eppendorf, 20246 Hamburg, Germany; k.prieske@uke.de (K.P.); j.hambrecht@uke.de (J.H.); a.jaeger@uke.de (A.J.)"],["dc.contributor.affiliation","Hampl, Monika; 3Department of Gynecology, University Medical Center Duesseldorf, 40225 Duesseldorf, Germany; hampl@med.uni-duesseldorf.de"],["dc.contributor.affiliation","Eulenburg, Christine zu; 4Department of Epidemiology, UMCG, Universität Groningen, 9713 Groningen, The Netherlands; christine.eulenburg@googlemail.com"],["dc.contributor.affiliation","Prieske, Katharina; 1Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg—Eppendorf, 20246 Hamburg, Germany; k.prieske@uke.de (K.P.); j.hambrecht@uke.de (J.H.); a.jaeger@uke.de (A.J.)"],["dc.contributor.affiliation","Hambrecht, Johanna; 1Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg—Eppendorf, 20246 Hamburg, Germany; k.prieske@uke.de (K.P.); j.hambrecht@uke.de (J.H.); a.jaeger@uke.de (A.J.)"],["dc.contributor.affiliation","Fuerst, Sophie; 6Department of Obstetrics and Gynecology, University Hospital, LMU—University of Munich, 80377 Munich, Germany; sophie.fuerst@med.uni-muenchen.de (S.F.); sven.mahner@med.uni-muenchen.de (S.M.)"],["dc.contributor.affiliation","Klapdor, Ruediger; 7Department of Obstetrics and Gynecology, Hannover Medical School, 30625 Hannover, Germany; klapdor.ruediger@mh-hannover.de"],["dc.contributor.affiliation","Heublein, Sabine; 8Department of Obstetrics and Gynecology, University Hospital Heidelberg, 69120 Heidelberg, Germany; sabine.heublein@med.uni-heidelberg.de"],["dc.contributor.affiliation","Gass, Paul; 9Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany; paul.gass@uk-erlangen.de"],["dc.contributor.affiliation","Rohner, Annika; 10Department of Gynecology, University Medical Center Tuebingen, 72076 Tuebingen, Germany; Annika.Rohner@med.uni-tuebingen.de"],["dc.contributor.affiliation","Canzler, Ulrich; 11Department of Gynecology and Obstetrics, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany & National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany; ulrich.canzler@uniklinikum-dresden.de"],["dc.contributor.affiliation","Becker, Sven; 12Department of Gynecology and Obstetrics, University Medical Center Frankfurt, 60590 Frankfurt, Germany; sven.becker@kgu.de"],["dc.contributor.affiliation","Bommert, Mareike; 13Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, 45136 Essen, Germany; m.bommert@kem-med.com"],["dc.contributor.affiliation","Bauerschlag, Dirk; 14Department of Gynecology, University Medical Center Kiel, 24105 Kiel, Germany; dirk.bauerschlag@uksh.de"],["dc.contributor.affiliation","Denecke, Agnieszka; 15Department of Gynecology, Medical Center Wolfsburg, 38440 Wolfsburg, Germany; agnieszka.denecke@klinikum.wolfsburg.de"],["dc.contributor.affiliation","Hanker, Lars; 16Department of Gynecology and Gynecologic Oncology, University Medical Center Luebeck, 23562 Luebeck, Germany; lars.hanker@uksh.de"],["dc.contributor.affiliation","Runnebaumn, Ingo; 17Department of Gynecology, Jena University Hospital, 07743 Jena, Germany; Ingo.Runnebaum@med.uni-jena.de"],["dc.contributor.affiliation","Forner, Dirk M.; 18Department of Gynecology, Evangelisches Krankenhaus Kalk, 51103 Cologne, Germany; dirk.forner@evkk.de"],["dc.contributor.affiliation","Schochter, Fabienne; 19Department of Obstetrics and Gynecology, University of Ulm Medical Center, 89081 Ulm, Germany; fabienne.schochter@uniklinik-ulm.de"],["dc.contributor.affiliation","Klar, Maximilian; 20Department of Gynecology, University Medical Center Freiburg, 79106 Freiburg, Germany; maximilian.klar@uniklinik-freiburg.de"],["dc.contributor.affiliation","Schwab, Roxana; 21Department of Gynecology, University Medical Center Mainz, 55131 Mainz, Germany; Roxana.Schwab@unimedizin-mainz.de"],["dc.contributor.affiliation","Koepke, Melitta; 22Department of Obstetrics and Gynaecology, University Hospital Augsburg, 86156 Augsburg, Germany; melitta.koepke@uk-augsburg.de (M.K.); christian.dannecker@med.uni-augsburg.de (C.D.)"],["dc.contributor.affiliation","Kalder, Matthias; 23Department of Gynecology and Obstetrics, University Hospital Marburg, 35043 Marburg, Germany; kalder@med.uni-marburg.de"],["dc.contributor.affiliation","Hantschmann, Peer; 24Department of Gynecology and Obstetrics, Medical Center Altoetting, 84503 Altoetting, Germany; p.hantschmann@innklinikum.de"],["dc.contributor.affiliation","Ratiu, Dominik; 25Department of Gynecology, University Medical Center Koeln, 50937 Koeln, Germany; dominik.ratiu@uk-koeln.de"],["dc.contributor.affiliation","Denschlag, Dominik; 26Department of Gynecology, Hochtaunuskliniken, 61352 Bad Homburg, Germany; dominik.denschlag@hochtaunus-kliniken.de"],["dc.contributor.affiliation","Schroeder, Willibald; 27Department of Gynecology, Medical Center Gynaecologicum Bremen, 28209 Bremen, Germany; prof.schroeder@gynaekologikum-bremen.de"],["dc.contributor.affiliation","Tuschy, Benjamin; 28Department of Gynecology, University Medical Center Mannheim, 68167 Mannheim, Germany; benjamin.tuschy@umm.de"],["dc.contributor.affiliation","Baumann, Klaus; 29Department of Gynecology, Medical Center Ludwigshafen, 67063 Ludwigshafen, Germany; baumann@klilu.de"],["dc.contributor.affiliation","Mustea, Alexander; 30Department of Gynecology and Gynecologic Oncology, University Medical Center Bonn, 53127 Bonn, Germany; alexander.mustea@ukbonn.de"],["dc.contributor.affiliation","Soergel, Philipp; 31Department of Gynecology, University Medical Center Minden, 32429 Minden, Germany; philipp.soergel@muehlenkreiskliniken.de"],["dc.contributor.affiliation","Bronger, Holger; 32Department of Gynecology and Obstetrics, Technical University of Munich, 81675 Munich, Germany; holger.bronger@tum.de"],["dc.contributor.affiliation","Bauerschmitz, Gerd; 33Department of Gynecology, University Medical Center Goettingen, 37075 Goettingen, Germany; gerd.bauerschmitz@med.uni-goettingen.de"],["dc.contributor.affiliation","Kosse, Jens; 34Department of Gynecology, Sana Klinikum Offenbach, 63069 Offenbach am Main, Germany; jens.kosse@sana.de"],["dc.contributor.affiliation","Koch, Martin C.; 35Department of Gynecology, Medical Center Ansbach, 91522 Ansbach, Germany; martin.koch@anregiomed.de"],["dc.contributor.affiliation","Ignatov, Atanas; 36Department of Obstetrics and Gynecology, University Hospital Magdeburg, 39120 Magdeburg, Germany; atanas.ignatov@med.ovgu.de"],["dc.contributor.affiliation","Sehouli, Jalid; 37Department of Gynecology with Center for Oncological SurgeryNOGGO e.V., Charite Universitatsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Virchow Campus Clinic, Charité Medical University, 13353 Berlin, Germany; jalid.sehouli@charite.de"],["dc.contributor.affiliation","Dannecker, Christian; 22Department of Obstetrics and Gynaecology, University Hospital Augsburg, 86156 Augsburg, Germany; melitta.koepke@uk-augsburg.de (M.K.); christian.dannecker@med.uni-augsburg.de (C.D.)"],["dc.contributor.affiliation","Mahner, Sven; 6Department of Obstetrics and Gynecology, University Hospital, LMU—University of Munich, 80377 Munich, Germany; sophie.fuerst@med.uni-muenchen.de (S.F.); sven.mahner@med.uni-muenchen.de (S.M.)"],["dc.contributor.affiliation","Jaeger, Anna; 1Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg—Eppendorf, 20246 Hamburg, Germany; k.prieske@uke.de (K.P.); j.hambrecht@uke.de (J.H.); a.jaeger@uke.de (A.J.)"],["dc.contributor.author","Woelber, Linn"],["dc.contributor.author","Hampl, Monika"],["dc.contributor.author","Eulenburg, Christine zu"],["dc.contributor.author","Prieske, Katharina"],["dc.contributor.author","Hambrecht, Johanna"],["dc.contributor.author","Fuerst, Sophie"],["dc.contributor.author","Klapdor, Ruediger"],["dc.contributor.author","Heublein, Sabine"],["dc.contributor.author","Gass, Paul"],["dc.contributor.author","Rohner, Annika"],["dc.contributor.author","Jaeger, Anna"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.editor","Preti, Mario"],["dc.contributor.editor","Querleu, Denis"],["dc.date.accessioned","2022-02-01T10:31:45Z"],["dc.date.available","2022-02-01T10:31:45Z"],["dc.date.issued","2022"],["dc.date.updated","2022-02-09T13:18:26Z"],["dc.description.abstract","The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b."],["dc.description.abstract","The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b."],["dc.identifier.doi","10.3390/cancers14020418"],["dc.identifier.eissn","2072-6694"],["dc.identifier.pii","cancers14020418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98940"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Geburtshilfe und Frauenheilkunde"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Hellriegel, Martin"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.author","Emons, Guenter"],["dc.date.accessioned","2018-11-07T09:20:27Z"],["dc.date.available","2018-11-07T09:20:27Z"],["dc.date.issued","2013"],["dc.format.extent","871"],["dc.identifier.doi","10.1055/s-0033-1350813"],["dc.identifier.isi","000325552500009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28879"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1438-8804"],["dc.relation.issn","0016-5751"],["dc.title","Breast Cancer Local Recurrence following ductal-invasive Breast Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2616"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Cells"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Kolb, Katharina"],["dc.contributor.author","Hellinger, Johanna"],["dc.contributor.author","Kansy, Maike"],["dc.contributor.author","Wegwitz, Florian"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.author","Emons, Günter"],["dc.contributor.author","Gründker, Carsten"],["dc.date.accessioned","2021-04-14T08:26:32Z"],["dc.date.available","2021-04-14T08:26:32Z"],["dc.date.issued","2020"],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.3390/cells9122616"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81981"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2073-4409"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Influence of ARHGAP29 on the Invasion of Mesenchymal-Transformed Breast Cancer Cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","914"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Der Gynäkologe"],["dc.bibliographiccitation.lastpage","919"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Bauerschmitz, G. J."],["dc.contributor.author","Hellriegel, M."],["dc.contributor.author","Emons, G."],["dc.date.accessioned","2020-12-10T14:08:43Z"],["dc.date.available","2020-12-10T14:08:43Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00129-017-4156-6"],["dc.identifier.eissn","1433-0393"],["dc.identifier.issn","0017-5994"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70534"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Palliative Konzepte beim Endometrium‑, Zervix- und Vulvakarzinom"],["dc.title.alternative","Palliative concepts for endometrial, cervical and vulvar cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2713"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Oncology"],["dc.bibliographiccitation.lastpage","2721"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Gruendker, Carsten"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.author","Schubert, Antje"],["dc.contributor.author","Emons, Guenter"],["dc.date.accessioned","2018-11-07T10:13:49Z"],["dc.date.available","2018-11-07T10:13:49Z"],["dc.date.issued","2016"],["dc.description.abstract","S100 calcium binding protein A4 (S100A4) and cysteine-rich angiogenic inducer 61 (CYR61) play important roles in epithelial-mesenchymal-transition (EMT), invasion and metastasis by promoting cancer cell motility. Recently we were able to show that invasion of GnRH receptor-positive breast cancer cells is time- and dose-dependently reduced by GnRH analogs. We have now analyzed whether GnRH treatment affects S100A4 and CYR61 in mesenchymal transformed breast cancer cells. S100A4 and CYR61 expression was analyzed using RT-PCR. Invasion was quantified by assessment of breast cancer cell migration rate through an artificial basement membrane. The role of S100A4 and CYR61 in invasion of breast cancer cells was analyzed by neutralizing their biological activity. Expression of S100A4, CYR61 and GnRH receptor in human breast cancers, normal and other non-malignant breast tissues was analyzed by immunohistochemistry. Invasion and expression of S100A4 and CYR61 in MDA-MB-231 breast cancer cells were significant higher as compared with MCF-7 breast cancer cells. Invasion and expression of S100A4 and CYR61 were significantly increased in mesenchymal transformed MCF-7 cells (MCF-7-EMT). The increased invasion of MCF-7-EMT cells could be reduced by anti-S100A4 and anti-CYR61 antibodies. In addition, invasion of MDA-MB-231 cells was decreased by anti-S100A4 and anti-CYR61 antibodies. Treatment of MCF-7-EMT and MDA-MB-231 cells with GnRH agonist Triptorelin resulted in a significant decrease of invasion and expression of S100A4 and CYR61. Both, S100A4 and CYR61 were found highly expressed in biopsy specimens of breast hyperplasia and malignant breast cancers. GnRH receptor expression was detectable in approximately 71% of malignant breast cancers. Our findings suggest that S100A4 and CYR61 play major roles in breast cancer invasion. Both, invasion and expression of S100A4 and CYR61 can be inhibited by GnRH treatment."],["dc.identifier.doi","10.3892/ijo.2016.3491"],["dc.identifier.isi","000375807900049"],["dc.identifier.pmid","27098123"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40506"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1791-2423"],["dc.relation.issn","1019-6439"],["dc.title","Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","41"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Breast Cancer Research and Treatment"],["dc.bibliographiccitation.lastpage","50"],["dc.bibliographiccitation.volume","152"],["dc.contributor.author","Gruendker, Carsten"],["dc.contributor.author","Bauerschmitz, Gerd"],["dc.contributor.author","Knapp, Juliane"],["dc.contributor.author","Schmidt, Elena"],["dc.contributor.author","Olbrich, Theresa"],["dc.contributor.author","Emons, Gunter"],["dc.date.accessioned","2018-11-07T09:55:28Z"],["dc.date.available","2018-11-07T09:55:28Z"],["dc.date.issued","2015"],["dc.description.abstract","Recently we have shown that breast cancer cell invasion was dramatically increased when co-cultured with MG63 cells. In addition we have generated mesenchymal transformed MCF-7 breast cancer cells (MCF-7-EMT), showing significantly increased invasion in contrast to wild type MCF-7 cells (MCF-7 WT). In this study we have analyzed whether stromal derived factor-1 (SDF-1) is responsible for MCF-7 and T-47-D breast cancer cell invasion and epithelial-mesenchymal-transition (EMT). In addition we have analyzed whether kisspeptin-10 (KP-10) treatment affects SDF-1-induced invasion and EMT. Invasion was quantified by assessment of MCF-7 and T-47-D breast cancer cell migration rate through an artificial basement membrane in a modified Boyden chamber during co-culture with MG63 cells or after treatment with SDF-1 alpha, SDF-1 beta or the combination of both isoforms. Induction of EMT was verified by analysis of protein expression of epithelial marker E-cadherin (CDH1) and mesenchymal markers N-cadherin (CDH2) and Vimentin (VIM). The role of SDF-1 for invasion and induction of EMT in breast cancer cells was analyzed by blocking SDF-1 secretion during co-culture with MG63 cells. In addition effects of KP-10 treatment on SDF-1-induced invasion and EMT were analyzed. Breast cancer cell invasion was significantly increased when co-cultured with MG63 cells. During co-culture SDF-1 protein expression of MG63 cells was significantly induced. The increased breast cancer cell invasion could be blocked by anti-SDF-1 antibodies. Treatment of breast cancer cells in monoculture (without MG63) with SDF-1 alpha, SDF-1 beta or the combination of both isoforms resulted in a significant escalation of breast cancer cell invasion and induction of EMT. Protein expression of mesenchymal markers CDH2 and VIM was clearly elevated, whereas protein expression of epithelial marker CDH1 was clearly decreased. The SDF-1-induced increase of cell invasion was significantly reduced after treatment with KP-10. In addition, induction of EMT was inhibited. Furthermore, protein expression of the binding site of SDF-1, CXC-motive-chemokine receptor 4 (CXCR-4), was reduced by KP-10. Treatment of MCF-7-EMT cells with KP-10 resulted in a significant drop of cell invasion and CXCR-4 protein expression. Our findings suggest that SDF-1 plays a major role in breast cancer invasion and EMT. SDF-1-induced invasion and EMT can be inhibited by KP-10 treatment by down-regulating CXCR-4 expression."],["dc.description.sponsorship","Deutsche Krebshilfe-Dr. Mildred Scheel Stiftung"],["dc.identifier.doi","10.1007/s10549-015-3463-7"],["dc.identifier.isi","000356248900005"],["dc.identifier.pmid","26062751"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36743"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-7217"],["dc.relation.issn","0167-6806"],["dc.title","Inhibition of SDF-1/CXCR4-induced epithelial-mesenchymal transition by kisspeptin-10"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1018"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Der Gynäkologe"],["dc.bibliographiccitation.lastpage","1023"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Emons, G."],["dc.contributor.author","Kiesel, L."],["dc.contributor.author","Bauerschmitz, G."],["dc.contributor.author","Ortmann, O."],["dc.date.accessioned","2020-12-10T14:08:44Z"],["dc.date.available","2020-12-10T14:08:44Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00129-018-4318-1"],["dc.identifier.eissn","1433-0393"],["dc.identifier.issn","0017-5994"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70540"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Therapie der Präkanzerosen und des frühen Endometriumkarzinoms"],["dc.title.alternative","Treatment of precancerous lesions and early endometrial cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]